Skip to content
Not evaluated by SAHPRA · For information & research use only · Not intended to diagnose, treat, cure or prevent any disease · Consult a healthcare professional
This product has not been evaluated by SAHPRA. For information purposes only — not intended to diagnose, treat, cure or prevent any disease.
← Back to shop
Weight LossResearch vialGLP-1GIPWeight lossOnce weeklyDual agonist

Tirzepatide

Dual GLP-1 + GIP agonist — deeper weight loss with cleaner GI per kilo lost.

R 1 560
30mg vial
Dual receptor actionActivates GLP-1 and GIP receptors simultaneously for amplified metabolic effect.
Up to 20.9% lossSURMOUNT-1 reported 20.9% mean weight loss at 15 mg over 72 weeks.
Insulin sensitisationGIP arm appears to amplify insulin response and improve glucose handling.
Better GI toleranceLower side-effect burden per unit of weight loss compared with single-receptor analogs.
Tirzepatide is a synthetic dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The added GIP arm appears to amplify insulin sensitisation and may reduce the gastrointestinal side-effect burden per unit of weight loss. Administered subcutaneously once weekly.
Distributor
Elegant Slimming · Mokopane, Limpopo, South Africa
WhatsApp 076 547 8764 · Mon–Sat 9–5
Regulatory
This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.